Investigating immunoproteasome inhibition
A new therapeutic approach to prevent chronic antibody-mediated rejection of renal allografts: Within ten years after transplantation approximately half of renal transplants are lost on average by chronic, antibody-mediated graft rejection. In this project we could show in rats that the inhibition of the immunoproteasome prevents the chronic rejection of transplanted kidneys. Plasma cells, which produce the allo-antibodies directed against the transplanted kidneys, were killed by inhibition of the immunoproteasome.